
==== Front
PLoS One
PLoS One
plos
PLOS ONE
1932-6203
Public Library of Science San Francisco, CA USA

10.1371/journal.pone.0302612
PONE-D-24-13134
Research Article
Medicine and Health Sciences
Medical Conditions
Infectious Diseases
Viral Diseases
Covid 19
Medicine and Health Sciences
Vascular Medicine
Thromboembolism
Medicine and Health Sciences
Vascular Medicine
Thromboembolism
Venous Thromboembolism
Deep Vein Thrombosis
Medicine and Health Sciences
Epidemiology
Medical Risk Factors
Medicine and Health Sciences
Pulmonology
Pulmonary Embolism
Medicine and Health Sciences
Vascular Medicine
Thromboembolism
Venous Thromboembolism
Pulmonary Embolism
Medicine and Health Sciences
Hematology
Blood Coagulation
Coagulation Disorders
Thrombosis
Medicine and Health Sciences
Medical Conditions
Cardiovascular Diseases
Coagulation Disorders
Thrombosis
Medicine and Health Sciences
Cardiology
Cardiovascular Medicine
Cardiovascular Diseases
Coagulation Disorders
Thrombosis
Medicine and Health Sciences
Vascular Medicine
Thrombosis
Medicine and Health Sciences
Medical Conditions
Cardiovascular Diseases
Cardiovascular Disease Risk
Medicine and Health Sciences
Cardiology
Cardiovascular Medicine
Cardiovascular Diseases
Cardiovascular Disease Risk
Biology and Life Sciences
Anatomy
Cardiovascular Anatomy
Blood Vessels
Veins
Jugular Vein
Medicine and Health Sciences
Anatomy
Cardiovascular Anatomy
Blood Vessels
Veins
Jugular Vein
Incidence and risk of post-COVID-19 thromboembolic disease and the impact of aspirin prescription; nationwide observational cohort at the US Department of Veteran Affairs
Incidence and risk of post-COVID-19 thromboembolic disease and the impact of aspirin prescription
https://orcid.org/0000-0003-3333-7833
Ware Anna D. Conceptualization Data curation Formal analysis Investigation Methodology Project administration Resources Software Validation Visualization Writing – original draft Writing – review & editing 1 *
Veigulis Zachary P. Conceptualization Data curation Formal analysis Investigation Methodology Writing – original draft 1 2
Hoover Peter J. Data curation Formal analysis Writing – original draft Writing – review & editing 1
Blumke Terri L. Conceptualization Data curation Formal analysis Writing – original draft Writing – review & editing 1
Ioannou George N. Conceptualization Formal analysis Writing – original draft Writing – review & editing 3 4
https://orcid.org/0000-0002-3695-192X
Boyko Edward J. Conceptualization Formal analysis Writing – original draft Writing – review & editing 5
Osborne Thomas F. Conceptualization Formal analysis Supervision Writing – original draft Writing – review & editing 1 6
1 National Center for Collaborative Healthcare Innovation, VA Palo Alto Healthcare System, Palo Alto, California, United States of America
2 Department of Business Analytics, University of Iowa Tippie College of Business, Iowa City, Iowa, United States of America
3 Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, United States of America
4 Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, United States of America
5 Seattle Epidemiologic Research and Information Center, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, United States of America
6 Department of Radiology, Stanford University School of Medicine, Stanford, California, United States of America
Serra Raffaele Editor
University Magna Graecia of Catanzaro, ITALY
Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Anna.Ware@va.gov
17 9 2024
2024
19 9 e03026128 5 2024
25 6 2024
https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Introduction

COVID-19 triggers prothrombotic and proinflammatory changes, with thrombotic disease prevalent in up to 30% SARS-CoV-2 infected patients. Early work suggests that aspirin could prevent COVID-19 related thromboembolic disorders in some studies but not others. This study leverages data from the largest integrated healthcare system in the United States to better understand this association. Our objective was to evaluate the incidence and risk of COVID-19 associated acute thromboembolic disorders and the potential impact of aspirin.

Methods

This retrospective, observational study utilized national electronic health record data from the Veterans Health Administration. 334,374 Veterans who tested positive for COVID-19 from March 2, 2020, to June 13, 2022, were included, 81,830 of whom had preexisting aspirin prescription prior to their COVID-19 diagnosis. Patients with and without aspirin prescriptions were matched and the odds of post-COVID acute thromboembolic disorders were assessed.

Results

10.1% of Veterans had a documented thromboembolic disorder within 12 months following their COVID-19 diagnosis. Those with specific comorbidities were at greatest risk. Preexisting aspirin prescription was associated with a significant decrease risk of post-COVID-19 thromboembolic disorders, including pulmonary embolism (OR [95% CI]: 0.69 [0.65, 0.74]) and deep vein thrombosis (OR [95% CI]: 0.76 [0.69, 0.83], but an increased risk of acute arterial diseases, including ischemic stroke (OR [95% CI]: 1.54 [1.46, 1.60]) and acute ischemic heart disease (1.33 [1.26, 1.39]).

Conclusions

Findings demonstrated that preexisting aspirin prescription prior to COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolism and pulmonary embolism but increased risk of acute arterial disease. The risk of arterial disease may be associated with increased COVID-19 prothrombotic effects superimposed on preexisting chronic cardiovascular disease for which aspirin was already prescribed. Prospective clinical trials may help to further assess the efficacy of aspirin use prior to COVID-19 diagnosis for the prevention of post-COVID-19 thromboembolic disorders.

The author(s) received no specific funding for this work. Data AvailabilityDue to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic data sets used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is consistent with other studies based on VA data. However, VA data are made freely available to researchers with an approved VA study protocol. For more information, please visit https://www.virec.research.va.gov or contact the VA Information Resource Center at VIReC@va.gov.
OutbreaksCOVID-19
Data Availability

Due to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic data sets used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is consistent with other studies based on VA data. However, VA data are made freely available to researchers with an approved VA study protocol. For more information, please visit https://www.virec.research.va.gov or contact the VA Information Resource Center at VIReC@va.gov.
==== Body
pmcIntroduction

As of June 13th, 2023, an estimated 879,548 Veterans have been infected with SARS-CoV2, with 24,777 known COVID-19 deaths, and many suffering the long-term effects of the infection [1, 2]. Early in the pandemic, major health impacts of the disease were thought to be the consequence of the associated severe viral pneumonia [3, 4]. Since then, evidence demonstrates that COVID-19 triggers prothrombotic and proinflammatory changes throughout the body which can have multi-systemic adverse outcomes during and after acute infection [5–11]. In fact, multiple clinical trials and observational studies have documented thrombotic disease in 25–30% SARS-CoV-2 infected patients, primarily in seriously ill patients [12–19]. Other researchers have suggested that aspirin use could prevent post-COVID acute thromboembolic disorders, although results thus far have been mixed [20–22]. Without further evidence, current clinical guidelines recommend that patients diagnosed with COVID-19 do not initiate low-dose antiplatelet therapy (i.e., aspirin) for the prevention of thromboembolism associated with SARS-CoV-2 infection [23].

The Veterans Health Administration (VHA) is the largest integrated healthcare system in the United States (U.S.), providing care for over 9 million enrolled Veterans [24]. Veterans represent a statistically older population with multiple comorbidities and are therefore at a greater risk for COVID-19 complications and poorer outcomes compared to the general public [25]. The aims of this study were to 1) assess the incidence of post-acute COVID-19 associated thromboembolic disorders within our population, 2) identify risk factors for post-acute COVID-19 thromboembolic disorders, and 3) quantify the potential impact that preexisting aspirin use had on the risk of post-acute COVID-19 thromboembolic disorders.

Materials and methods

Data source and patients

We performed a retrospective observational analysis from March 2nd, 2020, until June 13th, 2023, of Veterans aged 18 years or older who were diagnosed with COVID-19. For this analysis, data was accessed from the VHA’s electronic health record (EHR) database, the Corporate Data Warehouse (CDW) [26], between May 11th, 2023, and June 13th, 2023. Queries were developed to extract and collate patient demographic and clinical information.

Patients with a documented COVID-19 polymerase chain reaction (PCR) lab test from March 2nd, 2020, until June 13th, 2022, were identified. A 12-month follow-up period following the patient’s first positive COVID-19 PCR test for incidence of post-COVID-19 acute thromboembolic disorders was included, making the full assessment timeline from March 2nd, 2020, until June 13th, 2023. Patients with a negative or not-detected test result, those with a non-PCR or antigen lab, or patients with an incomplete Care Assessment of Needs (CAN) score within 6 months prior to their COVID-19 PCR lab test were excluded from the analysis (cohort inclusion/exclusion flowchart depicted in Fig 1). The CAN score is automatically calculated weekly on all living Veterans who are actively assigned to primary care panels [27, 28], and was utilized to inform current health status as well as identify patients actively utilizing VA care.

10.1371/journal.pone.0302612.g001 Fig 1 Patient flowchart.

Variables

The first documented positive COVID-19 PCR test during the patient’s latest episode of SARS-CoV2 infection was captured as the index date. For example, if a patient tested positive for COVID-19 in March 2020, then again in August 2021, with positive tests every two weeks through October 2021 for the 2nd infection, we captured the positive test in August 2021 as our index date.

Similar to methodologies established elsewhere [4, 29], VHA’s EHR data was utilized to assess aspirin use. In short, aspirin use was defined as patients with an active aspirin prescription at the time of their index date. If a patient had no refills at this time, the prescription was only considered active if it was filled within 30 days prior to the index date. Patients who had an active non-VHA aspirin prescription documented in their EHR were also included in the aspirin cohort. All other patients in the cohort with no documented active aspirin prescription were classified as controls.

Thromboembolic disorders were captured using ICD-10 codes documented within the patient’s EHR. This included venous thromboembolic disorders (pulmonary embolism (PE), deep vein thrombosis (DVT), cerebral venous sinus thrombosis (CVST), and other venous thromboembolic disorders), as well as arterial thromboembolic disorders (ischemic stroke, ischemic heart disease, and other arterial thromboembolic disorders). ICD-10 codes and their respective definitions can be found in S1 Table.

Additional covariates included age, sex, self-identified race or ethnicity, the CAN 1-Year Mortality score (Model Version 2.5), the Charlson Comorbidity Index (CCI), body mass index (BMI), common comorbidities, inpatient status at index date, COVID-19 vaccination status, the number of COVID-19 vaccine doses at the index date, and all-cause mortality within the follow-up period. The CAN score incorporates multiple structured data elements, including socio-demographics, diagnoses, vital signs, medications, lab values, and healthcare utilization data in its calculation and was utilized to quantify a patient’s health risk. The score ranges from 0 to 99, with higher scores representing a greater risk of mortality [4, 26, 30].

Statistical analysis

To assess post-COVID-19 acute thromboembolic disorders, contingency tables and unadjusted odds ratios were analyzed for any associations between the aspirin and control groups using the complete cohort. To mitigate potential confounding effects resulting from the retrospective observational nature of our dataset, propensity score matching (PSM) was utilized to match and compare patients in the aspirin vs control groups using the “nearest-neighbor” method within the RStudio “MatchIt” library (Version 3.6.2) [31] on the unscaled covariates of age, gender, and CAN score. Vaccination status was not included as a covariate in the matching algorithm since our assessment demonstrated that it was not significantly associated with the treatment assignment nor the outcome. We then produced contingency tables and adjusted odds ratios for post-COVID-19 acute thromboembolic disorders. Odds ratios are reported as point estimates with 95% confidence intervals for the aspirin cohort with the control cohort as reference.

To identify Veterans at highest risk for post-COVID-19 acute thromboembolic disorders, we examined the association of each outcome subgroup using multivariate logistic regression models adjusting for the covariates of age, sex, BMI, CCI, race and/or ethnicity, and common comorbidities prior to the index date as a sub-analysis using the complete cohort. The CAN score was not included in this part of the analysis due to multicollinearity.

This study was approved by Stanford Institutional Review Board (Stanford University, Stanford, CA, USA; IRB #60725). Given the retrospective nature of our study and the minimal risk it posed to participants, the Stanford IRB granted this study a waiver for informed consent. This decision aligns with the ethical standards set forth in the 1964 Helsinki declaration and its later amendments, ensuring that all study procedures were conducted with the utmost respect for participant rights and privacy.

Results

Baseline patient characteristics

Of the 334,374 COVID-19 positive Veterans in our cohort, 24.5% had an active aspirin prescription prior to their index date (Fig 1). There was significant variation between groups at baseline in the complete cohort, demonstrating the need for PSM (Table 1). After PSM, 163,660 patients (81,830 aspirin users and non-users) were included in the analysis with an average (SD) age of 69.6 (10.8) years, 94.4% of the cohort were male, and average (SD) CAN score was 57.3 (26.7). Density plots of the matched covariates demonstrated optimal balance after PSM (S1 Fig).

10.1371/journal.pone.0302612.t001 Table 1 Patient characteristics before and after propensity score matching.

	Complete Cohort	Propensity Score Matched Cohort*	
Non-Users (N = 252544)	Aspirin Users (N = 81830)	Non-Users (N = 81830)	Aspirin Users (N = 81830)	
Matched Patient Characteristics					
 Age (years), mean (SD)	57.7 (16.4)	69.6 (10.8)	69.6 (10.8)	69.6 (10.8)	
 Male	217090 (86.0%)	77245 (94.4%)	77245 (94.4%)	77245 (94.4%)	
 CAN 1 Year Mortality Score, mean (SD)	38.8 (30.3)	57.3 (26.7)	57.3 (26.7)	57.3 (26.7)	
Non-Matched Patient Characteristics					
Race and/or Ethnicity					
 Non-Hispanic White	140166 (55.5%)	50167 (61.3%)	49468 (60.5%)	50167 (61.3%)	
 Non-Hispanic Black or African American	59295 (23.5%)	18775 (22.9%)	18778 (22.9%)	18775 (22.9%)	
 Hispanic	28784 (11.4%)	6442 (7.9%)	6673 (8.2%)	6442 (7.9%)	
 Asian	3767 (1.5%)	660 (0.8%)	643 (0.8%)	660 (0.8%)	
 American Indian or Alaska Native	2638 (1.0%)	779 (1.0%)	813 (1.0%)	779 (1.0%)	
 Native Hawaiian/Other Pacific Islander	2266 (0.9%)	687 (0.8%)	659 (0.8%)	687 (0.8%)	
 Declined	12178 (4.8%)	3711 (4.5%)	3864 (4.7%)	3711 (4.5%)	
 Missing	3450 (1.4%)	609 (0.7%)	932 (1.1%)	609 (0.7%)	
Aspirin Dosage (mg/day), mean (SD)	NA	98.4 (61.9)	NA	98.4 (61.9)	
 81 mg/day	NA	76976 (91.6%)	NA	76976 (91.6%)	
 162 mg/day	NA	1172 (1.4%)	NA	1172 (1.4%)	
 243 mg/day	NA	50 (0.1%)	NA	50 (0.1%)	
 325 mg/day	NA	3022 (3.7%)	NA	3022 (3.7%)	
 405–650 mg/day	NA	45 (0.0%)	NA	45 (0.0%)	
 No Dose Listed (Non-VA prescription)	NA	565 (0.7%)	NA	565 (0.7%)	
CCI Score, mean (SD)	2.23 (2.90)	4.14 (3.21)	3.92 (3.22)	4.14 (3.21)	
Body Mass Index (BMI), mean (SD)	30.8 (6.42)	30.6 (6.24)	29.9 (6.29)	30.6 (6.24)	
Common Comorbidities Prior to COVID-19 Diagnosis					
 Congestive Heart Failure	26305 (10.4%)	20604 (25.2%)	14140 (17.3%)	20604 (25.2%)	
 Chronic Pulmonary Disease	82704 (32.7%)	38334 (46.8%)	35478 (43.4%)	38334 (46.8%)	
 Chronic Kidney Disease	33428 (13.2%)	21198 (25.9%)	17295 (21.1%)	21198 (25.9%)	
 Diabetes	32874 (13.0%)	16500 (20.2%)	13778 (16.8%)	16500 (20.2%)	
 Hypertension	134755 (53.4%)	71040 (86.8%)	59741 (73.0%)	71040 (86.8%)	
Inpatient for COVID-19	78586 (31.1%)	35212 (43.0%)	35057 (42.8%)	35212 (43.0%)	
Vaccinated status for COVID-19					
 Unvaccinated at time of COVID diagnosis	173230 (68.6%)	55193 (67.4%)	55693 (68.1%)	56602 (67.4%)	
 Vaccinated at time of COVID diagnosis	79314 (31.4%)	26637 (32.6%)	26137 (31.9%)	27403 (32.6%)	
Number Vaccine Doses prior to COVID-19 Diagnosis					
 Unvaccinated	173230 (68.6%)	55193 (67.4%)	55693 (68.1%)	55193 (67.4%)	
 1 Dose	8855 (3.5%)	2157 (2.6%)	2345 (2.9%)	2157 (2.6%)	
 2 Doses	37887 (15.0%)	10879 (13.3%)	10869 (13.3%)	10879 (13.3%)	
 3 Doses	32572 (12.9%)	13601 (16.6%)	12923 (15.8%)	13601 (16.6%)	
Death within follow-up period	26254 (10.4%)	7531 (9.2%)	13890 (17.0%)	7531 (9.2%)	
CAN = Care Assessment Needs, CCI = Charelson Comorbidity Index

*Propensity Score Matching was performed using the “nearest neighbor” method in R Studio (Version 3.6.2) through the “MatchIt” library, matching on the covariates of age, gender, and the VA’s Care Assessment of Needs (CAN) 1-Year Mortality Score.

Risk factors for post-COVID-19 acute thromboembolic disorders

In our sub-analysis using the complete cohort prior to PSM, we found that those with any post-acute COVID-19 thromboembolic disorders had higher incidences of prior diagnoses compared to those without post-acute COVID-19 thromboembolic disorders. Specifically, these included congestive heart failure (CHF) (34.7% vs. 11.7%), chronic pulmonary disease (52.3% vs. 34.4%), chronic kidney disease (CKD) (35.4% vs. 14.2%), and hypertension (HTN) (89.7% vs. 58.8%; S2 Table). When assessing the odds of any thromboembolic disorders in the complete cohort, we observed an increased risk among older patients (OR [95% CI]: 1.03 [1.03, 1.03]), Black or African Americans (1.12 [1.08, 1.15]), males (1.26 [1.20, 1.33]), and for those diagnosed with CHF (1.45 [1.41, 1.50]), or HTN (1.56 [1.50, 1.62]). These increased risks were consistent across all subgroups of thromboembolic disorders (S2 Fig).

Post-COVID-19 acute thromboembolic disorders

Prior to PSM, 10.1% of Veterans had documentation of any post-acute COVID-19 thromboembolic disease within the follow-up period (Table 2). This increased to 14.4% after matching on key baseline characteristics. The most prevalent among the case and control groups, respectively were ischemic stroke (6.9% vs. 4.6%, p<0.001), ischemic heart disease (4.8% vs. 3.7%, p<0.001), PE (2.1% vs. 3.0%, p<0.001), other venous thromboembolic disorders (2.1% vs. 2.8%, p<0.001), other arterial thromboembolic disorders (1.7% vs 1.3%, p<0.001), and DVT (1.1% vs. 1.3%, p<0.001).

10.1371/journal.pone.0302612.t002 Table 2 Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date.

	Complete Unmatched Cohort	PSM Matched Cohort*	
Overall (N = 334,374)	Non- Aspirin (N = 252544)	Aspirin Users (N = 81830)	p-value+	Overall (N = 163660)	Non- Aspirin (N = 81830)	Aspirin Users (N = 81830)	p-value+	
Any Thromboembolic Disorders	33925 (10.1%)	21233 (8.4%)	12692 (15.5%)	<0.001	23643 (14.4%)	10951 (13.4%)	12692 (15.5%)	<0.001	
Venous Thromboembolic Disorders									
 Pulmonary Embolism	6728 (2.0%)	5021 (2.0%)	1707 (2.1%)	0.223	4148 (2.5%)	2441 (3.0%)	1707 (2.1%)	<0.001	
 Deep Vein Thrombosis	3206 (1.0%)	2336 (0.9%)	870 (1.1%)	0.002	1949 (1.2%)	1079 (1.3%)	870 (1.1%)	<0.001	
 Cerebral Venous Sinus Thrombosis	75 (0.0%)	53 (0.0%)	22 (0.0%)	0.619	39 (0.0%)	17 (0.0%)	22 (0.0%)	0.726	
 Other Venous Thromboembolic Disorders1	6289 (1.9%)	4594 (1.8%)	1695 (2.1%)	<0.001	3947 (2.4%)	2252 (2.8%)	1695 (2.1%)	<0.001	
Arterial Thromboembolic Disorders									
 Ischemic Stroke	12532 (3.7%)	6867 (2.7%)	5665 (6.9%)	<0.001	9432 (5.8%)	3767 (4.6%)	5665 (6.9%)	<0.001	
 Ischemic Heart Disease (STEMI/NSTEMI)	9626 (2.9%)	5676 (2.2%)	3950 (4.8%)	<0.001	6964 (4.3%)	3014 (3.7%)	3950 (4.8%)	<0.001	
 Other Arterial Thromboembolic Disorders2	3314 (1.0%)	1911 (0.8%)	1403 (1.7%)	<0.001	2472 (1.5%)	1069 (1.3%)	1403 (1.7%)	<0.001	
*Propensity Score Matching (PSM) was performed using the “nearest neighbor” method in R Studio (Version 3.6.2) through the “MatchIt” library, matching on the covariates of age, gender, and the VA’s Care Assessment of Needs (CAN) 1-Year Mortality Score.

+Chi-Sq and T-test used to determine significant associations between groups.

1Other Venous Thromboembolic Disorders includes acute embolism and thrombosis of the axillary, subclavian, internal jugular, superior vena cava, inferior vena cava, renal, and other thoracic veins. Also, acute embolism and thrombosis of other specified deep veins of lower extremities and veins of upper extremities.

2Other Arterial Thromboembolic Disorders includes both arterial embolism and thrombosis, and renal embolism and thrombosis.

Aspirin’s relationship with post-COVID-19 acute thromboembolic disorders

After PSM, aspirin use was associated with decreased risk of PE (OR [95% CI]: 0.69 [0.65, 0.74]), DVT (0.76 [0.69, 0.83]) and other venous thromboembolic disorders (0.73 [0.69, 0.78]; Table 3 & Fig 2). However, there we observed an increased risk of post-COVID-19 arterial diseases, including ischemic stroke (OR [95% CI]: 1.54 [1.46, 1.60]), acute ischemic heart disease (1.33 [1.26, 1.39]), and other arterial thromboembolic disorders (1.32 [1.22, 1.43]).

10.1371/journal.pone.0302612.g002 Fig 2 Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disorders within the follow-up period among the propensity score matched cohort (N = 168010).

10.1371/journal.pone.0302612.t003 Table 3 Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disorders within the follow-up period.

	Complete Unmatched Cohort (N = 334374)	PSM Matched Cohort* (N = 163660)	
Unadjusted ORs	Adjusted ORs	
(95% CIs)	(95% CIs)	
Any Thromboembolic Disorders	2.00 (1.95, 2.05)	1.19 (1.16, 1.22)	
Venous Thromboembolic Disorders			
 Pulmonary Embolism	1.05 (0.99, 1.11)	0.69 (0.65, 0.74)	
 Deep Vein Thrombosis	1.15 (1.06, 1.24)	0.76 (0.69, 0.83)	
 Cerebral Venous Sinus Thrombosis	1.28 (0.76, 2.08)	1.05 (0.56, 1.99)	
 Other Venous Thromboembolic Disorders1	1.14 (1.07, 1.20)	0.73 (0.69, 0.78)	
Arterial Thromboembolic Disorders			
 Ischemic Stroke	2.66 (2.59, 2.78)	1.54 (1.47, 1.60)	
 Acute Ischemic Heart Disease (STEMI/NSTEMI)	2.21 (2.12, 2.30)	1.33 (1.26, 1.39)	
 Other Arterial Thromboembolic Disorders2	2.29 (2.13, 2.45)	1.32 (1.22, 1.43)	
Significant odds ratios (OR) are bolded (p<0.05

*Propensity Score Matching (PSM) was performed using the “nearest neighbor” method in R Studio (Version 3.6.2) through the “MatchIt” library, matching on the covariates of age, gender, and the VA’s Care Assessment of Needs (CAN) 1-Year Mortality Score.

**Adjusted for CAN 1-Year Mortality Score, Male, and Age in models prior to PSM matching

1Other Venous Thromboembolic Disorders includes acute embolism and thrombosis of the axillary, subclavian, internal jugular, superior vena cava, inferior vena cava, renal, and other thoracic veins. Also, acute embolism and thrombosis of other specified deep veins of lower extremities and veins of upper extremities.

2Other Arterial Thromboembolic Disorders includes arterial embolism and thrombosis and renal embolism and thrombosis.

Discussion

COVID-19 can trigger systemic inflammatory and prothrombotic changes in the body, leading to negative adverse acute and long-term outcomes including cardiovascular disease [9–15]. As a result, researchers have speculated that aspirin could prevent some of the debilitating post-acute COVID-19 conditions such as thromboembolic disorders [5–8]. However, results have varied thus far and have been inconclusive [21, 22]. This study leveraged historical operational data from over 330,000 medical records, at the largest integrated healthcare system within the U.S., to help clarify associations.

We found that 10.1% of our cohort were diagnosed with any post-acute COVID-19 thromboembolic disorders within 12-months following their SARS-CoV2 infection. This rate is significantly greater than the expected baseline yearly incidence of thromboembolic disorders [32], yet similar to other reports of post COVID-19 thrombotic disease incidence [15]. Overall risk factors most strongly associated with post-COVID-19 acute thromboembolic disorders include older patients, males, those self-identified as Black or African American, and those with comorbidities such as CHF and HTN.

Interestingly, our findings demonstrate contrasting associations with venous and arterial thromboembolic disease risk for those taking aspirin vs those not taking aspirin prior to being diagnosed with COVID-19. Specifically, COVID-19 positive Veterans with preexisting aspirin prescriptions had a decreased risk of venous thromboembolic disorders, but an increased risk of arterial thromboembolic diseases during the follow-up period. Since daily aspirin use is typically prescribed as a prophylaxis for arterial thromboembolic disease [33], our observed arterial disease results could potentially reflect the biased baseline population risks in the aspirin group. Therefore, Veterans who were predetermined by their clinician to be at increased risk for arterial disease and were prophylactically taking aspirin to reduce that risk might have a superimposed higher risk during a prothrombotic state from COVID-19 that the antithrombotic effects of aspirin could not overcome.

Strengths of this study include that our analysis was performed on a large population-based assessment of Veterans, utilizing data from a nationwide integrated healthcare system, in which diagnoses, medication use, and laboratory studies are all observable. VHA is in a unique position to assess OTC medications because VHA can directly provide Veterans with OTC medications and systematically documents all active medications for those who acquire OTCs elsewhere. Additionally, while a handful of previous studies attempted to assess the effects of aspirin on post-COVID thromboembolic disorders [21, 22], there were limitations in the ability to distinguish between historical, chronic, and acute aspirin uses. In contrast, our assessment presents associations for our cohort who were prescribed daily aspirin prior to their COVID-19 diagnosis, and not as a new or historical-inactive treatment.

Our results are limited as our Veteran population may face unique Veteran related health challenges [1], therefore, these associations may not be generalizable to non-VHA settings. Although our PSM models demonstrated balance across covariates, they were not able to eliminate the expected confounding that was related to the association of daily aspirin being prescribed to those who are clinically determined to be at higher risk for cardiovascular disease. As this is a retrospective evaluation, we cannot establish direct cause and effect, and therefore future randomized-control trials required to assess the potential of aspirin as a drug repurposing option to prevent post-COVID acute thromboembolic disorders.

Conclusion

Preexisting aspirin prescription at the time of COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolic disorders and an increased risk of arterial thromboembolic disease. The risk of arterial disease may, in part, be associated with preexisting arterial disease that triggered the historical daily aspirin prescription before COVID-19 diagnosis. Prospective clinical trials are required to assess the efficacy and appropriateness of aspirin use prior to COVID-19 diagnosis for the prevention of acute post-COVID-19 thromboembolic disorders.

Supporting information

S1 Fig Density plots displaying the balance on the matched covariates of age, gender, and the VA’s Care Assessment of Needs (CAN) 1-Year Mortality score before and after propensity score matching using the “nearest neighbor” method in R Studio (Version 3.6.2).

(DOCX)

S2 Fig Subgroup analyses of the odds of post-COVID-19 acute thromboembolic disorders using the complete cohort (N = 334,374).

(DOCX)

S1 Table ICD-10 Codes and definitions for acute thromboembolic disorders included in the analysis.

(DOCX)

S2 Table Sub-analysis cohort characteristics among those with and without thromboembolic disorders within 12 months following the patient’s index date using the complete cohort (N = 334,374).

(DOCX)

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Department of Veterans Affairs.

10.1371/journal.pone.0302612.r001
Decision Letter 0
Serra Raffaele Academic Editor
© 2024 Raffaele Serra
2024
Raffaele Serra
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
27 May 2024

PONE-D-24-13134Incidence and Risk of Post-COVID-19 Thromboembolic Disease and the Impact of Aspirin Prescription; Nationwide Observational Cohort at the US Department of Veteran Affairs.PLOS ONE

Dear Dr. Ware,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript is overall well written. Only minor revisions are required.

Please submit your revised manuscript by Jul 11 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Raffaele Serra, M.D., Ph.D

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

The manuscript requires only minor revisions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study leverages data from the largest integrated healthcare system in the United States to better understand this association. I suggest to include in the references the following paper : Ielapi N, et al. Malattia cardiovascolare come biomarker per un aumento del rischio di infezione da COVID-19 e relativa prognosi sfavorevole. BioMark Med. 2020 giugno;14(9):713-716. doi: 10.2217/bmm-2020-0201, because it is in line with the issue of this paper. I suggest a extensive revision of the language.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0302612.r002
Author response to Decision Letter 0
Submission Version1
29 May 2024

PLOS ONE

May 29, 2024

RE: Manuscript Number: PONE-D-24-13134

Dear Editors,

Thank you for the opportunity to revise our manuscript entitled, “Incidence and Risk of Post-COVID-19 Thromboembolic Disease and the Impact of Aspirin Prescription; Nationwide Observational Cohort at the US Department of Veteran Affairs.” for publication in the PLOS ONE. We sincerely appreciate the reviewers’ comments and have made considerable efforts to address them. Please see the table below for a point-by-point response to reviewer.

Reviewer 1 Comments: This study leverages data from the largest integrated healthcare system in the United States to better understand this association. I suggest to include in the reference the following paper: Ielapi N, et al. Malattia cardiovascolare come biomarker per un aumento del rischio di infezione da COVID-19 e relativa prognosi sfavorevole. BioMark Med. 2020 giugno;14(9):713-716. doi: 10.2217/bmm-2020-0201, because it is in line with the issue of this paper. I suggest a extensive revision of the language.

Authors Response: Thank you for this assessment of our work. We appreciate your thoughtful and thorough suggestions. I have added the following reference to the introduction of our paper following the sentence, “Since then, evidence demonstrates that COVID-19 triggers prothrombotic and proinflammatory changes throughout the body which can have multi-systemic adverse outcomes during and after acute infection” on page 4 as I concur that it is pertinent to this manuscript:

• Ielapi N, Licastro N, Provenzano M, Andreucci M, Franciscis S, Serra R. Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis. Biomark Med. 2020 Jun;14(9):713-716. doi: 10.2217/bmm-2020-0201. Epub 2020 May 19. PMID: 32426991; PMCID: PMC7236792.

Additionally, I have re-read through the manuscript and edited the language to be more clear, correct, and unambiguous.

Specifically:

• In the introduction on page 4, line 82:

o “Other researcher suggest that aspirin…” has been changed to: “Other researchers have suggested that aspirin…”

• In the introduction on page 4, lines 90-92:

o “The aims of this study were to 1) assess the incidence of COVID-19 associated acute thromboembolic disorders…” has been adjusted to state: “The aims of this study were to 1) assess the incidence of post-acute COVID-19 associated thromboembolic disorders within our population…”

• In the introduction on page 4, lines 94-96:

o “3) quantify the potential impact that preexisting aspirin use had on the risk of thromboembolic disease.” has been modified to state “3) quantify the potential impact that preexisting aspirin use had on the risk of post-acute COVID-19 thromboembolic disorders.”

• In the methods section on page 5, line 111:

o “…weekly on all living Veterans assigned to primary care panels.” was modified to: “…weekly on all living Veterans who are actively assigned to primary care panels.”

• In the methods section on page 6, line 120-122:

o “… the prescription was only considered active if it was filled up to 30 days prior to the index date.” was modified to state: “…the prescription was only considered active if it was filled within 30 days prior to the index date.”

• In the methods section on page 6, line 125:

o “Thromboembolic disorders were captured using ICD-10 codes within the patient’s EHR.” was edited to “Thromboembolic disorders were captured using ICD-10 codes documented within the patient’s EHR.”

• In the methods section on page 6, line 132:

o “…vaccination status and the number of vaccine doses at the index date, and all-cause mortality within the follow-up period.” was modified to add clarification: “…COVID-19 vaccination status, the number of COVID-19 vaccine doses at the index date, and all-cause mortality within the follow-up period.”

• In the results section on page 7, lines 164-166:

o “Of the 334,374 COVID-19 Veterans in our cohort, 24.5% had an active aspirin prescription prior to their index date.” we added clarification on the cohort by stating “Of the 334,374 COVID-19 positive Veterans in our cohort, 24.5% had an active aspirin prescription prior to their index date.”

• In the results section on page 8, lines 167-168:

o “After PSM, 163,660 patients (81,830 aspirin users and non-users) were included in the analysis with an average (SD) age was 69.6 (10.8) years, 94.4% were male, and average (SD) CAN score was 57.3 (26.7)” was modified to state “After PSM, 163,660 patients (81,830 aspirin users and non-users) were included in the analysis with an average (SD) age of 69.6 (10.8) years, 94.4% of the cohort were male, and average (SD) CAN score was 57.3 (26.7).”

• In the results section on page 8, lines 173-181:

o “In our sub-analysis using the complete cohort prior to PSM, those with an incidence of any post-acute COVID-19 thromboembolic disorders vs not, were prior diagnoses of congestive heart failure (CHF) (34.7% vs. 11.7%), chronic pulmonary disease (52.3% vs. 34.4%), CKD (35.4% vs. 14.2%), and hypertension (HTN) (89.7% vs. 58.8%; Supp Table 2). When assessing the odds of any thromboembolic disorders in the complete cohort, there was an increased risk among older patients (OR [95% CI]: 1.03 [1.03, 1.03]), Black or African Americans (1.12 [1.08, 1.15]), male (1.26 [1.20, 1.33]), and for those diagnosed with CHF (1.45 [1.41, 1.50]), or HTN (1.56 [1.50, 1.62]) across all subgroups of thromboembolic disorders (Supp Figure 2).” was modified to state: “In our sub-analysis using the complete cohort prior to PSM, we found that those with any post-acute COVID-19 thromboembolic disorders had higher incidences of prior diagnoses compared to those without post-acute COVID-19 thromboembolic disorders. Specifically, these included congestive heart failure (CHF) (34.7% vs. 11.7%), chronic pulmonary disease (52.3% vs. 34.4%), chronic kidney disease (CKD) (35.4% vs. 14.2%), and hypertension (HTN) (89.7% vs. 58.8%; Supp Table 2). When assessing the odds of any thromboembolic disorders in the complete cohort, we observed an increased risk among older patients (OR [95% CI]: 1.03 [1.03, 1.03]), Black or African Americans (1.12 [1.08, 1.15]), males (1.26 [1.20, 1.33]), and for those diagnosed with CHF (1.45 [1.41, 1.50]), or HTN (1.56 [1.50, 1.62]). These increased risks were consistent across all subgroups of thromboembolic disorders (Supp Figure 2).”

• In the results section on page 8, lines 173-182:

o “Prior to PSM, 10.1% of Veterans had a condition typically related to thromboembolic disease within the follow-up period.” was modified to: “Prior to PSM, 10.1% of Veterans had documentation of any post-acute COVID-19 thromboembolic disease within the follow-up period (Table 2).”

• In the discussion section on page 9, lines 210-219:

o “Interestingly, our findings demonstrate opposite venous and arterial thromboembolic disease risk associations for those taking aspirin vs not prior to being diagnosed with COVID-19… Because daily aspirin use is typically prescribed as a prophylaxis for arterial thromboembolic disease, our observed arterial disease results could potentially reflect the biased baseline population risks in the aspirin group. Therefore, Veterans who were predetermined to be at increased risk for arterial disease by their clinician and prophylactically taking aspirin to reduce that risk may have a superimposed higher risk during a prothrombotic state from COVID-19 that the antithrombotic effects of aspirin could not overcome.” was modified to state: “Interestingly, our findings demonstrate contrasting associations with venous and arterial thromboembolic disease risk for those taking aspirin vs those not taking aspirin prior to being diagnosed with COVID-19….Since daily aspirin use is typically prescribed as a prophylaxis for arterial thromboembolic disease, our observed arterial disease results could potentially reflect the biased baseline population risks in the aspirin group. Therefore, Veterans who were predetermined by their clinician to be at increased risk for arterial disease and were prophylactically taking aspirin to reduce that risk might have a superimposed higher risk during a prothrombotic state from COVID-19 that the antithrombotic effects of aspirin could not overcome.”

• In the discussion section on page 9, line 234:

o “Strengths of this study include a large population-based assessment of Veterans…”was modified to state: “Strengths of this study include that our analysis was performed on a large population-based assessment of Veterans…”

I hope the manuscript will meet the high standards of the PLOS ONE. We look forward to hearing from you at your earliest convenience.

Best regards,

Anna Ware, MPH, MS

Attachment Submitted filename: Response to Reviewers.docx

10.1371/journal.pone.0302612.r003
Decision Letter 1
Serra Raffaele Academic Editor
© 2024 Raffaele Serra
2024
Raffaele Serra
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
26 Jun 2024

Incidence and Risk of Post-COVID-19 Thromboembolic Disease and the Impact of Aspirin Prescription; Nationwide Observational Cohort at the US Department of Veteran Affairs.

PONE-D-24-13134R1

Dear Dr. Ware,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Raffaele Serra, M.D., Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

amended manuscript is acceptable.

Reviewers' comments:

10.1371/journal.pone.0302612.r004
Acceptance letter
Serra Raffaele Academic Editor
© 2024 Raffaele Serra
2024
Raffaele Serra
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
2 Jul 2024

PONE-D-24-13134R1

PLOS ONE

Dear Dr. Ware,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Raffaele Serra

Academic Editor

PLOS ONE
==== Refs
References

1 COVID-19 National Summary | Veterans Affairs. https://www.accesstocare.va.gov/Healthcare/COVID19NationalSummary. Accessed June 13th, 2023.
2 Raman B , Bluemke DA , Lüscher TF , Neubauer S . Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022 Mar 14;43 (11 ):1157–1172. doi: 10.1093/eurheartj/ehac031 .35176758
3 Ochani R , Asad A , Yasmin F , Shaikh S , Khalid H , Batra S , et al . COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021 Mar 1;29 (1 ):20–36. .33664170
4 Osborne TF , Veigulis ZP , Arreola DM , Mahajan SM , Röösli E , Curtin CM . Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021 Feb 11;16 (2 ):e0246825. doi: 10.1371/journal.pone.0246825 .33571280
5 Restrepo MI , Marin-Corral J , Rodriguez JJ , Restrepo V , Cavallazzi R . Cardiovascular Complications in Coronavirus Disease 2019-Pathogenesis and Management. Semin Respir Crit Care Med. 2023 Feb;44 (1 ):21–34. doi: 10.1055/s-0042-1760096 Epub 2023 Jan 16. .36646083
6 Violi F , Cammisotto V , Pignatelli P . Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets. 2021 Nov 17;32 (8 ):1009–1017. doi: 10.1080/09537104.2021.1936478 Epub 2021 Jun 7. .34097572
7 Meizlish ML , Goshua G , Liu Y , Fine R , Amin K , Chang E , et al . Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol. 2021 Apr 1;96 (4 ):471–479. doi: 10.1002/ajh.26102 Epub 2021 Feb 22. .33476420
8 Al Harthi AF , Aljuhani O , Korayem GB , Altebainawi AF , Alenezi RS , Al Harbi S , et al . Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. J Intensive Care Med. 2022 Sep;37 (9 ):1238–1249. doi: 10.1177/08850666221093229 Epub 2022 Apr 21. .35450493
9 Lodigiani C , Iapichino G , Carenzo L , Cecconi M , Ferrazzi P , Sebastian T , et al . Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Jul;191 :9–14. doi: 10.1016/j.thromres.2020.04.024 Epub 2020 Apr 23. .32353746
10 Ma S. , Su W. , Sun C. et al . Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis. Eur J Clin Pharmacol 78 , 1403–1420 (2022). doi: 10.1007/s00228-022-03356-5 35732963
11 Ielapi N , Licastro N , Provenzano M , Andreucci M , Franciscis S , Serra R . Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis. Biomark Med. 2020 Jun;14 (9 ):713–716. doi: 10.2217/bmm-2020-0201 Epub 2020 May 19. .32426991
12 Klok FA , Kruip MJHA , van der Meer NJM , Arbous MS , Gommers DAMPJ , Kant KM , et al . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. (2020) 191 :145–7. doi: 10.1016/j.thromres.2020.04.013 32291094
13 Wichmann D , Sperhake JP , Lütgehetmann M , Steurer S , Edler C , et al . Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. (2020). doi: 10.7326/M20-2003 32374815
14 Cui S , Chen S , Li X , Liu S , Wang F . Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. (2020) 18 :1421–4. doi: 10.1111/jth.14830 32271988
15 Violi F , Cammisotto V , Pignatelli P . Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets. 2021 Nov 17;32 (8 ):1009–1017. doi: 10.1080/09537104.2021.1936478 Epub 2021 Jun 7. .34097572
16 Xie Y. , Xu E. , Bowe B. et al . Long-term cardiovascular outcomes of COVID-19. Nat Med 28 , 583–590 (2022). doi: 10.1038/s41591-022-01689-3 35132265
17 Wu T. , Zuo Z. , Yang D. , Luo X. , Jiang L. , Xia Z. , et al . (2021). Venous Thromboembolic Events in Patients with COVID-19: A Systematic Review and Meta-Analysis. Age Ageing 50 (2 ), 284–293. doi: 10.1093/ageing/afaa259 33201226
18 Piazza G , Campia U , Hurwitz S , et al . Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. J Am Coll Cardiol. 2020 Nov, 76 (18 ) 2060–2072. doi: 10.1016/j.jacc.2020.08.070 33121712
19 Middeldorp S , Coppens M , van Haaps TF , et al . Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18 : 1995–2002. doi: 10.1111/jth.14888 32369666
20 Chuang YC , Tsai HW , Liu SA , Wu MJ , Liu PY . COVID-19 in Veterans: A Narrative Review. Risk Manag Healthc Policy. 2022 Apr 26;15 :805–815. doi: 10.2147/RMHP.S354814 .35502442
21 Zareef R , Diab M , Al Saleh T , Makarem A , Younis NK , Bitar F , et al . Aspirin in COVID-19: Pros and Cons. Front Pharmacol. 2022 Mar 10;13 :849628. doi: 10.3389/fphar.2022.849628 .35370686
22 Abdi M , Lamardi ZH , Shirjan F , Mohammadi L , Abadi SSD , Massoudi N , et al . The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review. Cardiovasc Hematol Agents Med Chem. 2022;20 (3 ):189–196. doi: 10.2174/1871525720666220401102728 .35366783
23 Barnes GD , Burnett A , Allen A , Ansell J , Blumenstein M , Clark NP , et al . Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022 Aug;54 (2 ):197–210. doi: 10.1007/s11239-022-02643-3 Epub 2022 May 17. .35579732
24 About VHA. Washington, DC: Veterans Health Administration, June 2023. (https://www.va.gov/health/aboutvha.asp). Accessed July 20, 2023.
25 Wang JZ, Dhanireddy P, Prince C, Larsen M, Schimpf M, Pearman G, Main results report, prepared for Strategic Analysis Service (SAS) Office of Strategic Planning and Analysis (OSPA) Veterans Health Administration. 2021 Survey of Veteran Enrollees’ Health and Use of Health Care.
26 US Department of Veterans Affairs. Corporate data warehouse (CDW). URL: www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm.
27 Osborne TF , Veigulis ZP , Arreola DM , Röösli E , Curtin CM . Automated EHR score to predict COVID-19 outcomes at US Department of Veterans Affairs. Plos One 2020;15 . doi: 10.1371/journal.pone.0236554 .32716922
28 Finh S, Box T. Care Assessment Need (CAN) Score and the Patient Care Assessment System (PCAS): Tools for Care Management https://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/713-notes.pdf Published 2013. Accessed April 30, 2020.
29 Albandar HJ , Markert R , Agrawal S . The relationship between aspirin use and mortality in colorectal cancer. Journal of Gastrointestinal Oncology. 2018;9 (6 ):1133–1137 doi: 10.21037/jgo.2018.08.13 .30603132
30 Dev S , Gonzalez AA , Coffing J , Slaven JE , Dev S , Taylor S , et al . Validating administratively derived frailty scores for use in Veterans Health Administration emergency departments. Acad Emerg Med. 2023 Apr;30 (4 ):349–358. doi: 10.1111/acem.14705 Epub 2023 Mar 28. .36847429
31 Greifer N. MatchIt: Getting started. https://cran.r-project.org/web/packages/MatchIt/vignettes/MatchIt.html. Published June 13, 2023.
32 Cushman M . Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007 Apr;44 (2 ):62–9. doi: 10.1053/j.seminhematol.2007.02.004 .17433897
33 Bhatt DL , Pollack CV Jr . The Future of Aspirin Therapy in Cardiovascular Disease. The American Journal of Cardiology. 2021 Apr 1;144 :S40–7. doi: 10.1016/j.amjcard.2020.12.019 33706989
